Valuation: Evaxion A/S

Market Cap 23.69M 20.81M 19.43M 17.83M 33.38M 2.27B 34.2M 230M 90.09M 1.12B 88.93M 87M 3.88B P/E 2026 *
-71x
P/E 2027 * 71x
Enterprise Value 23.69M 20.81M 19.43M 17.83M 33.38M 2.27B 34.2M 230M 90.09M 1.12B 88.93M 87M 3.88B EV / Sales 2026 *
-
EV / Sales 2027 * 1.4x
Free-Float
76.93%
Yield 2026 *
-
Yield 2027 * -
1 day+1.43%
1 week-6.58%
Current month-8.39%
1 month-11.25%
3 months-33.33%
6 months-16.47%
Current year-40.46%
1 week 2.8
Extreme 2.8
3.09
1 month 2.8
Extreme 2.8
3.6
Current year 2.8
Extreme 2.8
5.48
1 year 2.45
Extreme 2.45
12.15
3 years 1.2
Extreme 1.2
69.1
5 years 1.2
Extreme 1.2
1,252
10 years 1.2
Extreme 1.2
1,252
Manager TitleAgeSince
Corporate Officer/Principal 49 10/08/2008
Chief Executive Officer 59 23/11/2025
Director of Finance/CFO 53 31/10/2024
Director TitleAgeSince
Director/Board Member 56 31/12/2017
Chairman 52 31/12/2012
Director/Board Member 68 24/05/2021
Date Insider Type Main position Quantity % Market Cap.
16/04/26 Other

Director

2,376 0.0006%
18/03/26 Other

Director

483,391 0.1159%
18/03/26 Other

Chief Executive Officer

2,286,150 0.5482%
Change 5-day change 1-year change 3-year change Capi.($)
+1.43%-6.58%-3.40%-95.53% 23.69M
+0.71%+6.68%+0.73%+14.49% 48.95B
+1.90%+24.70%+27.25%+9.47% 40.75B
-1.60%-1.15%+388.84%+603.70% 38.46B
-0.98%+2.28%+7.02%+45.34% 36.38B
+1.47%+5.82%+5.76%+43.52% 28.45B
-0.94%+0.05% - - 16.62B
+2.44%+10.76%+30.59%+129.56% 16.33B
-1.14%+6.52%-3.80%-29.33% 13.65B
+0.76%+3.93%+4.00%+9.81% 13.56B
Average +0.33%+4.55%+50.78%+81.22% 25.32B
Weighted average by Cap. +0.25%+6.92%+71.97%+122.80%

Financials

2026 *2027 *
Net sales - 16.95M 14.89M 13.9M 12.76M 23.88M 1.62B 24.47M 165M 64.46M 803M 63.63M 62.25M 2.78B
Net income -15.78M -13.87M -12.95M -11.88M -22.24M -1.51B -22.79M -154M -60.03M -748M -59.26M -57.97M -2.59B -1.12M -980K -915K -839K -1.57M -107M -1.61M -10.85M -4.24M -52.86M -4.19M -4.1M -183M
Net Debt - -
Logo Evaxion A/S
Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Employees
46
Date Price Change Volume
29/07/26 US$2.840 +1.43% 13,406
28/07/26 US$2.800 -3.11% 21,208
27/07/26 US$2.890 -2.36% 12,101
24/07/26 US$2.960 -2.95% 3,354
23/07/26 US$3.050 +0.33% 10,385
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.840USD
Average target price
11.25USD
Spread / Average Target
+296.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EVAX Stock